Agilon Health, Inc. (AGL) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Agilon Health operates a platform partnering with physician groups to provide Medicare-centric, globally capitated care. As of June 30, 2024, the Company provided care to approximately 512,800 Medicare Advantage members (a 38% increase year-over-year) and 131,700 attributed beneficiaries in CMS ACO Models. The Company expanded operations into Lexington, Kentucky, and Augusta, Georgia, effective January 1, 2024.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenues | $1,482,758 | $1,069,115 | $3,087,112 | $2,123,427 |
| Medical Services Expense | $1,374,060 | $932,823 | $2,817,902 | $1,830,395 |
| Gross Profit | $32,175 | $54,576 | $107,263 | $127,699 |
| Net Loss (GAAP) | $(30,662) | $(16,795) | $(36,696) | $(836) |
| Adjusted EBITDA | $(2,830) | $12,469 | $26,224 | $36,507 |
| Cash & Equivalents | $109,490 | $107,570 | $109,490 | $107,570 |
| Marketable Securities | $291,622 | $380,773 | $291,622 | $380,773 |
| Total Debt Outstanding | $36,110 | $38,558 | $36,110 | $38,558 |
Note: Debt figures represent the sum of current portion ($8.75M) and long-term debt ($27.36M) as of June 30, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 39% in Q2 and 45% YTD, driven by a 36-39% increase in average membership due to seven new geographies and growth in existing markets.
- Margin Compression: Gross profit declined 41% in Q2 (from $54.6M to $32.2M) and 16% YTD. Medical margin decreased 21% in Q2 and 9% YTD. This was primarily due to higher medical services expense per member (up 9% in Q2, 11% YTD) and the dilutive effect of new members.
- Contract Terminations: Revenue and medical services expense were reduced by $55.9 million and $54.3 million, respectively, in Q2 2024 due to retroactive terminations of certain payor contracts effective January 1, 2024.
- Operating Expenses: General and administrative expenses decreased 12% in Q2 and 2% YTD, largely due to reduced investments in geography entry.
- Discontinued Operations: The Company recorded a loss of $9.3 million YTD 2024 related to the sale of its Hawaii operations, compared to income of $5.2 million in the prior year period.
Guidance, Outlook, and Risks
- Liquidity: The Company holds $116.3 million in cash and restricted cash and $291.6 million in marketable securities. It maintains a credit facility with $51.4 million available under the revolving portion. Management believes current resources are sufficient for the next 12 months.
- Outlook: The Company expects to continue incurring operating losses and generating negative cash flows from operations in the foreseeable future due to investments in expansion. Medical margin per member is expected to fluctuate as new members are added.
- Legal Proceedings: Three putative class action lawsuits were filed in early 2024 alleging securities fraud regarding medical utilization, claims rates, and profit margins. The Company cannot estimate the financial impact at this stage.
- Internal Controls: The Company disclosed a material weakness in internal control over financial reporting as of December 31, 2023. While remediation is ongoing, disclosure controls were deemed not effective as of June 30, 2024.
- Executive Change: Veeral Desai resigned as Chief Strategy and Development Officer on August 1, 2024, to assume a strategic advisor role.
Investor Verification Checklist
- Medical Margin Sustainability: Verify the drivers behind the 21% decline in Q2 medical margin and the 9% increase in medical expense per member.
- Contract Termination Impact: Assess the long-term revenue implications of the $55.9 million reduction from retroactive payor contract terminations.
- Legal Exposure: Monitor the status of the three securities class action lawsuits filed in Q1/Q2 2024.
- Internal Control Remediation: Review progress on remediation of the material weakness in internal controls over financial reporting.
- Cash Burn Rate: Evaluate the trajectory of negative operating cash flows ($66.5M used YTD 2024) against current liquidity reserves.